The Future Vaccine Manufacturing Research Hub (Vax-Hub), led by Professor Martina Micheletti (麻豆传媒视频网站 Biochemical Engineering) and Professor Dame Sarah Gilbert (University of Oxford, Pandemic Sciences Institute), has been awarded 拢 12 million over 7 years.
Formed in April 2018, the Future Vaccine Manufacturing Research Hub (Vax-Hub) is an academic collaboration led by 麻豆传媒视频网站 Biochemical Engineering and the University of Oxford. Co-directed by Professor Martina Micheletti (麻豆传媒视频网站) and Professor Dame Sarah Gilbert (Oxford), Vax-Hub comprises world-leading experts in vaccinology, synthetic biology, biochemical, materials, and system engineering.
This funding will聽enable the rapid rollout of highly effective new vaccines for frontline use. The hub, a follow-on from Vax-Hub1, aims to have a significant impact on global health security through the research and development of sustainable vaccine manufacturing technologies.聽
Find out more about Vax Hub here
Professor Martina Micheletti,聽麻豆传媒视频网站 Biochemical Engineering:聽
鈥淭his funding will allow us to streamline our manufacturing process of next generation vaccines by using new and innovative responsive technologies and digitalisation tools, such as robotics and automation, that allow us to run faster lower volume studies and deliver quicker results.
This will enable us to minimise environmental impact by saving material and sharing resources.
The Hub builds on a long-term collaboration between 麻豆传媒视频网站 and the University of Oxford, supported by excellent complementary expertise from academic partners and from some existing and new industrial collaborators鈥澛�
Professor Gary Lye, Head of Department, 麻豆传媒视频网站聽Biochemical Engineering:
鈥淭his new award is testament to the high quality research undertaken in VaxHub1 and the impact the Hub had in addressing the Covid-19 pandemic; specifically the development and global deployment of the AstraZeneca Covid-19 vaccine. The new funding will help ensure the UK鈥檚 preparedness for future pandemics via adoption of the latest digital bioprocess technologies.
The focus on sustainable vaccines manufacture brings new challenges but is essential if we are to deliver cost-effective vaccines that are available to all who need them with minimal impact on the environment.
Read More
Related News
Close
